Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01594619 · ClinicalTrials.gov registry record · Phase 1
Study in Healthy Volunteers to Investigate the Effects of Diltiazem on the Pharmacokinetics of Naloxegol
A Phase 1 study of Drug Induced Constipation, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT01594619: Completed Phase 1 study of Drug Induced Constipation, sponsored by AstraZeneca.
NCT01594619 is a Phase 1 study of Drug Induced Constipation that has completed, run by AstraZeneca. The registered enrollment target is 44 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01594619, a Phase 1 study of Drug Induced Constipation, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
Study in healthy volunteers to investigate the effects of Diltiazem on the Pharmacokinetics of naloxegol.
Conditions Studied
Interventions
- DRUG Naloxegol
- DRUG Diltiazem XR
Study Locations (1)
Kansas
- Research Site - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2012-05 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
What the finished NCT01594619 record still lists
NCT01594619 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% lower).
The record links to 1 condition, with Drug Induced Constipation appearing as the primary indexed condition, and to 2 interventions - of which Naloxegol is the first listed.
NCT01594619 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT01594619 about?
NCT01594619 is a clinical study titled "Study in Healthy Volunteers to Investigate the Effects of Diltiazem on the Pharmacokinetics of Naloxegol". Study in healthy volunteers to investigate the effects of Diltiazem on the Pharmacokinetics of naloxegol.
What is the current status of trial NCT01594619?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2012-05. Estimated completion is 2012-08.
What conditions does trial NCT01594619 study?
This clinical trial studies the following conditions: Drug Induced Constipation.
What interventions are being tested in trial NCT01594619?
The interventions under investigation include: Naloxegol (DRUG), Diltiazem XR (DRUG).
Who is sponsoring clinical trial NCT01594619?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01594619 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01594619's enrollment target sits among peer trials
44 1086th of 2000 higher than 901 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia